Total Payments
$1,079
2024 Payments
$460.64
Companies
22
Transactions
34
Medicare Patients
1,700
Medicare Billing
$176,381
Payment Breakdown by Category
Food & Beverage$902.97 (83.7%)
Education$176.15 (16.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $902.97 | 30 | 83.7% |
| Education | $176.15 | 4 | 16.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $165.78 | 3 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $154.46 | 2 | $0 (2024) |
| Janssen Biotech, Inc. | $113.12 | 5 | $0 (2024) |
| Exelixis Inc. | $88.85 | 1 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $80.19 | 3 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $58.48 | 2 | $0 (2023) |
| Daiichi Sankyo Inc. | $55.54 | 2 | $0 (2024) |
| Astellas Pharma US Inc | $48.06 | 2 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $43.89 | 1 | $0 (2019) |
| TerSera Therapeutics LLC | $31.17 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $460.64 | 19 | Janssen Biotech, Inc. ($67.88) |
| 2023 | $88.11 | 4 | Janssen Biotech, Inc. ($45.24) |
| 2019 | $43.89 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($43.89) |
| 2018 | $208.75 | 4 | AstraZeneca Pharmaceuticals LP ($127.70) |
| 2017 | $277.73 | 6 | Alexion Pharmaceuticals, Inc. ($165.78) |
All Payment Transactions
34 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $25.97 | General |
| Category: Oncology | ||||||
| 11/14/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $20.57 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.95 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $31.17 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $20.57 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $29.00 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Immunocore Limited | KIMMTRAK (Drug) | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: Oncology | ||||||
| 09/30/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.59 | General |
| Category: ONCOLOGY | ||||||
| 09/09/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $26.76 | General |
| Category: Oncology | ||||||
| 07/16/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $32.14 | General |
| Category: Oncology | ||||||
| 06/11/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA, TALVEY | Food and Beverage | In-kind items and services | $27.13 | General |
| Category: Oncology | ||||||
| 05/28/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $25.73 | General |
| Category: Hematology | ||||||
| 05/21/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: Oncology | ||||||
| 05/04/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $30.90 | General |
| Category: Oncology | ||||||
| 04/23/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $19.65 | General |
| Category: ONCOLOGY | ||||||
| 04/12/2024 | ABBVIE INC. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $13.79 | General |
| Category: ENDOCRINOLOGY | ||||||
| 02/22/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: Oncology | ||||||
| 01/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $24.54 | General |
| Category: ONCOLOGY | ||||||
| 11/28/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: Oncology | ||||||
| 10/31/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $25.06 | General |
| Category: Oncology | ||||||
| 09/25/2023 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: Oncology | ||||||
| 09/01/2023 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $20.78 | General |
| Category: Oncology | ||||||
| 10/16/2019 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $43.89 | General |
| Category: Oncology | ||||||
| 11/15/2018 | Novartis Pharmaceuticals Corporation | ILARIS (Biological) | Food and Beverage | In-kind items and services | $19.05 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 382 | 626 | $168,798 | $39,899 |
| 2022 | 9 | 457 | 824 | $201,231 | $46,903 |
| 2021 | 10 | 451 | 732 | $202,163 | $49,824 |
| 2020 | 9 | 410 | 641 | $188,090 | $39,755 |
Total Patients
1,700
Total Services
2,823
Medicare Billing
$176,381
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 111 | 180 | $56,520 | $13,177 | 23.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 152 | 264 | $56,232 | $12,349 | 22.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 39 | 63 | $26,586 | $7,230 | 27.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 53 | $11,130 | $3,365 | 30.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $7,744 | $1,698 | 21.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 22 | 22 | $6,974 | $1,396 | 20.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 25 | 28 | $3,612 | $683.76 | 18.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 183 | 374 | $79,662 | $18,215 | 22.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 100 | 162 | $50,868 | $11,801 | 23.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 33 | 44 | $18,568 | $4,788 | 25.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 27 | 81 | $17,010 | $4,592 | 27.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 20 | 23 | $9,200 | $2,368 | 25.7% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 20 | 56 | $6,440 | $1,721 | 26.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 23 | 23 | $7,291 | $1,470 | 20.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 40 | 50 | $6,450 | $1,274 | 19.8% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2022 | 11 | 11 | $5,742 | $673.87 | 11.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 128 | 201 | $63,114 | $15,232 | 24.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 138 | 251 | $53,463 | $12,801 | 23.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 39 | 60 | $25,320 | $6,654 | 26.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 34 | 82 | $17,220 | $4,623 | 26.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 25 | 25 | $12,100 | $2,758 | 22.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 18 | 18 | $10,818 | $2,696 | 24.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 20 | 23 | $9,200 | $2,513 | 27.3% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 25 | 44 | $5,060 | $1,326 | 26.2% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 12 | 12 | $3,804 | $812.76 | 21.4% |
About Dr. Aaron Alizadeh, M.D
Dr. Aaron Alizadeh, M.D is a Hematology & Oncology healthcare provider based in Decatur, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/26/2005. The National Provider Identifier (NPI) number assigned to this provider is 1063412567.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aaron Alizadeh, M.D has received a total of $1,079 in payments from pharmaceutical and medical device companies, with $460.64 received in 2024. These payments were reported across 34 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($902.97).
As a Medicare-enrolled provider, Alizadeh has provided services to 1,700 Medicare beneficiaries, totaling 2,823 services with total Medicare billing of $176,381. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Decatur, GA
- Active Since 07/26/2005
- Last Updated 12/01/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1063412567
Products in Payments
- SOLIRIS (Drug) $163.64
- TAGRISSO (Drug) $127.70
- Cabometyx (Drug) $88.85
- DARZALEX (Biological) $72.37
- KISQALI (Drug) $61.14
- Enhertu (Drug) $55.54
- NINLARO (Drug) $43.89
- Aliqopa (Drug) $37.70
- Zoladex (Drug) $31.17
- XPOVIO (Drug) $30.90
- ENHERTU (Biological) $26.76
- Vyloy (Drug) $25.97
- REBLOZYL (Biological) $25.73
- KEYTRUDA (Biological) $24.54
- VERZENIO (Drug) $24.30
- Padcev (Drug) $22.09
- Lenvima (Drug) $21.04
- Nubeqa (Drug) $20.78
- ELREXFIO (Drug) $20.57
- RYBREVANT (Drug) $20.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Decatur
Sebastien Kairouz, M.d, M.D
Hematology & Oncology — Payments: $41,840
Hematology & Oncology $41,840
Dr. Bruce Feinberg, Do, DO
Hematology & Oncology — Payments: $30,799
Hematology & Oncology $30,799
Mr. Perry Guaglianone, M.d, M.D
Hematology & Oncology — Payments: $19,173
Hematology & Oncology $19,173
Ana Antun, M.d, M.D
Hematology & Oncology — Payments: $17,709
Hematology & Oncology $17,709
Dr. Benjamin Esparaz, M.d, M.D
Hematology & Oncology — Payments: $14,881
Hematology & Oncology $14,881
Dr. Sammy Becdach, M.d, M.D
Hematology & Oncology — Payments: $8,595
Hematology & Oncology $8,595